SCHEMBL2922701

SCHEMBL2922701

CCCN1CCN(c2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 3/20 0.62
DRD2 P14416 7/20 0.57
KDM4E B2RXH2 1/20 0.56
GAA P10253 1/20 0.56
MAPT P10636 2/20 0.56
LMNA P02545 1/20 0.56
ALOX12 P18054 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
BCL2A1 Q16548 1/20 0.55
MAPK1 P28482 1/20 0.55
HTT P42858 1/20 0.55
SLC6A2 P23975 1/20 0.54
SLC6A4 P31645 1/20 0.54
SLC6A3 Q01959 1/20 0.54
DRD3 P35462 2/20 0.54
DRD1 P21728 1/20 0.54
DRD4 P21917 1/20 0.54
DRD5 P21918 1/20 0.54
HTR1A P08908 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28161148 0.90 BCL2A1 (0.67) SIGMAR1DRD2KDM4EGAAMAPT
SCHEMBL11938912 0.89 KDM4E (0.68) SIGMAR1DRD2KDM4EGAAMAPT
SCHEMBL10163611 0.86 BCL2A1 (0.63) SIGMAR1DRD2KDM4EGAAMAPT
SCHEMBL1254422 0.85 MAPT (0.57) SIGMAR1DRD2MAPTLMNAALOX12
SCHEMBL5185937 0.83 MAPT (0.60) SIGMAR1DRD2KDM4EGAAMAPT
SCHEMBL13079491 0.82 KDM4E (0.78) SIGMAR1DRD2KDM4EGAAMAPT
SCHEMBL2922525 0.82 DPP4 (0.52) SIGMAR1DRD2KDM4EGAAMAPT
SCHEMBL2927674 0.81 DRD2 (0.60) SIGMAR1DRD2KDM4EGAADRD3
SCHEMBL10006585 0.81 SIGMAR1 (0.64) SIGMAR1DRD2MAPTLMNAALOX12
SCHEMBL5186059 0.81 CYP2D6 (0.59) DRD2MAPTLMNAALOX12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE41315-E1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DE) 2010-05-04 US disclosed
US-6924374-B2 Central nervous system disorders; psychological disorders A. CARLSSON RESEARCH AB (SE) 2005-08-02 US disclosed
EP-1419773-A2 4-Phenylpiperidine derivatives as modulators of dopamine neurotransmission A. Carlsson Research AB (SE) 2004-05-19 EP disclosed
US-20030004169-A1 Modulators of dopamine neurotransmission NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) 2003-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004169-A1 Modulators of dopamine neurotransmission OPRD1, OPRK1, OPRM1 SIGMAR1 5/4885DRD2 16/4885KDM4E 3373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.